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Summary 
Background Internationally, smoking prevalence among people in prison custody (ie, people on remand awaiting 
trial, awaiting sentencing, or serving a custodial sentence) is high. In Scotland, all prisons implemented a 
comprehensive smoke-free policy in 2018 after a 16-month anticipatory period. In this study, we aimed to use data on 
medication dispensing to assess the impact of this policy on cessation support, health outcomes, and potential 
unintended consequences among people in prison custody.
Methods We did an interrupted time-series analysis using dispensing data for 44 660 individuals incarcerated in 
14 closed prisons in Scotland between March 30, 2014, and Nov 30, 2019. We estimated changes in dispensing rates 
associated with the policy announcement (July 17, 2017) and full implementation (Nov 30, 2018) using seasonal 
autoregressive integrated moving average models. Medication categories of primary interest were treatments for 
nicotine dependence (as an indicator of smoking cessation or abstinence attempts), acute smoking-associated 
illnesses, and mental health (antidepressants). We included antiepileptic medications as a negative control.
Findings A 44% step increase in dispensing of treatments for nicotine dependence was observed at implementation 
(2250 items per 1000 people in custody per fortnight, 95% CI 1875 to 2624) due primarily to a 42% increase in 
dispensing of nicotine replacement therapy (2109 items per 1000 people in custody per fortnight, 1701 to 2516). A 
9% step decrease in dispensing for smoking-related illnesses was observed at implementation, largely accounted for 
by respiratory medications (–646 items per 1000 people in custody per fortnight, –1111 to –181). No changes associated 
with announcement or implementation were observed for mental health dispensing or antiepileptic medications 
(control).
Interpretation Smoke-free prison policies might improve respiratory health among people in custody and encourage 
smoking abstinence or cessation without apparent short-term adverse effects on mental health dispensing.
Funding National Institute of Health Research Public Health Research programme, Scottish Government Chief 
Scientist Office, and UK Medical Research Council.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
In most countries worldwide, the prevalence of tobacco 
smoking among people in custody is high, in contrast to 
the decrease observed in the general population.1 For 
example, in Scotland in 2017, 68% of people in prison 
custody (refers to people on remand awaiting trial, 
awaiting sentencing, or serving a custodial sentence 
hereafter) were smokers compared with 18% of adults at 
liberty,2,3 and levels of second-hand smoke in prisons 
were comparable to those within a typical smoking 
home.4
Smoke-free policies in public places have resulted 
in substantial reductions in diseases associated with 
smoking and respiratory, irritant, and sensory symp-
toms.5 However, national smoking bans vary in whether 
they encompass custodial settings. In the UK, prisons 
were partially exempt from the 2006–07 legislation on 
smoke-free enclosed public places; in Scotland people in 
custody were permitted to smoke in their cells and 
during outdoor recreation.6
Although several jurisdictions worldwide have intro-
duced smoke-free prison policies,7 little evidence is 
available on the health impacts of such policies, 
particularly with regard to objective measures of health 
and health-care utilisation. A 2016 Cochrane review 
identified a need for more robust studies assessing the 
health impacts of smoking bans in institutional settings 
such as prisons, including both pre-ban and post-ban 
data and follow-up for longer than 6 months.8
In July, 2017, the Scottish Prison Service announced 
plans to implement a comprehensive smoke-free policy 
in the 15 prisons in their estate.4,9 This policy, which was 
implemented on Nov 30, 2018, prohibited smoking in all 
indoor and outdoor areas and was accompanied by high 
compliance and immediate, substantial improvements 
in indoor air quality.10
The Tobacco in Prisons study (TIPs) is a multi-method 
study with a natural experimental design, which has 
investigated the process and impacts of this policy, using 
objective air quality measurement; routinely collected 
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data; surveys, interviews, and focus groups with staff and 
people in custody; and health economic analyses.11 In this 
study, as part of TIPs, we assessed the impacts of this 
smoke-free policy on treatment for nicotine dependence 
(as a proxy for smoking cessation or abstinence attempts); 
specific smoking-associated illnesses; and mental health 
among people in custody, using routinely collected phar-
macy data on medication dispensing in Scottish prisons.
Methods 
Study design 
We used an interrupted time-series analysis to quantify 
changes in medication dispensing in Scottish prisons 
after the announcement of a smoke-free prisons policy 
and subsequent implementation of the policy. The 
population of interest comprised people in custody in 
Scottish prisons during the analysis period (March 30, 2014, 
to Nov 30, 2019). Primary analyses included all 14 closed 
prisons; secondary analyses also included Scotland’s one 
open prison. Details of the Scottish prison estate and 
population are available online.
We obtained anonymised individual-level dispensing 
data for people in custody from the single pharmacy 
provider, which manages procurement and reim-
burse ment of medications for Scottish prisons, via 
National Health Service (NHS) National Services Scotland. 
These data were based on individual patient medication 
records and stock (bulk) supply to prisons, and comprise 
all medications dispensed in Scottish prisons during the 
study period with the exception of nicotine replacement 
Research in context
Evidence before this study
Previous studies indicate that smoke-free policies in public places 
are associated with reductions in acute coronary syndromes, 
respiratory disease, and sensory symptoms. However, evidence 
of the health impacts of smoke-free policies in prisons and other 
institutional settings is scarce. We searched MEDLINE and 
Embase from database inception to Jan 5, 2021, for published 
studies on the impact of smoke-free policies in prisons, using 
synonyms for smoking restrictions ([“smok*” OR “tobacco”] 
AND [“ban” OR “prohib*”]) combined with those for custodial 
settings (“prison*” OR “incarcer*”)); and separately for studies on 
medication usage in relation to smoke-free policies in any 
context using synonyms for smoking restrictions combined with 
either terms for medication use (“prescrib*” OR “dispens*”) or for 
the specific conditions and medications of interest in this study.
Our search yielded 2608 studies. Studies in community settings 
have found significant associations between ambient air quality 
and medication dispensing for respiratory conditions, 
suggesting that medication dispensing might be a valid and 
sensitive indicator of acute health impacts. Previous research 
suggests potential reductions in mortality and acute 
myocardial infarction, and improvements in self-reported 
health, but might be biased by secular trends, seasonality, 
or changes in exposure or outcome measurement. Previous 
systematic reviews have identified a need for high-quality 
studies assessing the health impact of smoking bans in 
institutional settings such as prisons. To our knowledge, 
no previous studies have investigated objective indicators of 
health impacts among people in custody (including potential 
unintended harms) using robust designs able to account for 
underlying trends.
Added value of this study
Using routine medication dispensing data for 44 660 people in 
custody in Scottish prisons (regardless of custodial status) during 
a 5·7-year period, we found that the implementation of a 
comprehensive smoke-free policy was associated with a 
substantial increase in indicators of smoking cessation or 
abstinence attempts and improvements in indicators of 
respiratory health, with no evidence of changes in dispensing for 
mental health. In contrast to previous work in this area, 
our analyses accounted for underlying trends, seasonal effects, 
and autocorrelation, with our main findings evident in both 
modelling strategies used (seasonal autoregressive integrated 
moving average with prespecified breakpoints and indicator 
saturation with model-identified breakpoints). We found no 
change in dispensing rates for antiepileptic medications (control) 
in response to policy announcement or implementation, which 
strengthens our confidence in the potentially causal relationship 
between policy implementation and dispensing rates. 
This analysis is part of the first study internationally to assess the 
implementation of a comprehensive smoke-free policy across an 
entire prison system and, to our knowledge, represents the first 
use of medication dispensing to assess the impact of smoke-free 
policies in institutional settings on smoking-related health 
conditions and mental health.
Implications of all the available evidence
This study corroborates existing evidence from community 
settings that smoke-free policies can result in rapid and 
sustained improvements in respiratory health and extends this 
finding to institutional settings largely exempt from the UK 
smoke-free policy introduced in 2006–07 in public places. 
Findings are pertinent for other jurisdictions considering 
smoke-free prison policies. We found that a smoke-free policy 
had no apparent effect on antidepressant dispensing, which is 
reassuring with regard to potential unintended consequences 
for mental health, but does not exclude the possibility of 
potential negative impacts for some people who are in custody, 
especially among those most at risk of poor mental health. 
Medication dispensing seems to be a sensitive and widely 
available outcome indicator for monitoring population health 
impacts of tobacco control policies and air quality changes, 
especially for relatively mild symptoms that might not 
otherwise result in health-care utilisation, but which collectively 
could represent a substantial population burden.
For more on the Scottish prison 




www.thelancet.com/public-health   Published online September 16, 2021   https://doi.org/10.1016/S2468-2667(21)00163-8 3
therapy in one prison, which is managed by an in-reach 
service provided by the local health board. This prison was 
therefore excluded from analyses of nicotine replacement 
therapy but included in all other analyses.
Prison population data and contracted capacity for the 
study period were obtained from the Scottish Prison 
Service, based on the twice-weekly prison census. Prison 
population data were averaged to obtain a fortnightly 
mean population.
Mean dispensing rates per person for each medication 
category were calculated by dividing the sum of dispensed 
items by the mean prison population for each fortnightly 
unit (figure 1). Data cleaning techniques are described in 
detail in the appendix (p 1).
The TIPs study protocol was approved by the Scottish 
Prison Service Research Access and Ethics committee 
and University of Glasgow ethics committee. The analysis 
reported here used only de-identified dispensing records 
and aggregate prison population data, collected as part of 
routine health-care and prison service provision; thus the 
requirement for written informed consent was waived.
Outcomes 
Selection of medication categories as outcomes was based 
on an a priori set of criteria informed by the clinical and 
operational expertise of the co-investigators (appendix 
p 2). The key outcomes of interest were dispensing rates 
of medications for treatment of nicotine dependence (as a 
proxy for smoking cessation or abstinence attempts); for 
acute smoking-related conditions of the respiratory, 
cardiovascular, gastrointestinal and sensory systems; 
and anti depressants. The smoking-associated illnesses 
category included two categories strongly associated with 
tobacco smoking and second-hand smoke exposure 
(respiratory and cardiovascular) and two cat egories with a 
weaker association (gastro intestinal and sensory). Since 
data were not available on the conditions drugs were 
dispensed for, and a range of antibacterial drugs are used 
to treat lower respiratory tract infections, we chose to 
include all antibacterial drugs within the respiratory 
category. Since antidepressant medications might be 
used for indications other than mental health (eg, some 
tricyclic antidepressants are used for neuropathic pain), 
and in the absence of data on indication, we included a 
subgroup analysis for selective serotonin reuptake 
inhibitors (SSRIs) only, because this antidepressant class 
is most specific to mental health problems. Our original 
analysis plan did not include hypnotic and anxiolytic 
drugs in the mental health category due to the widespread 
use of benzodiazepines for alcohol detoxification in the 
prison setting; thus we did a post-hoc analysis of this 
category (appendix p 10). The rationale for not including 
opioid substitution therapy dispensing as a potential 
outcome category is included in the appendix (p 2).
Figure 1: Medications of interest included in the analysis and their grouping for analytical purposes
BNF=British National Formulary. COPD=chronic obstructive pulmonary disease. *The BNF is the pharmaceutical reference book used in the UK National Health Service.
Sensory: conjunctivitis and eye irritation
Anxiety and depression
Included medications
MedicationsLevel 2 groupingLevel 1 grouping BNF* chapters or codes
Indicators of smoking 
cessation or abstinence 
attempts
Indicators of smoking-
related illnesses or 
symptoms
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We also did an analysis of a control group of medications, 
expected to be unaffected by the inter vention, to address 
the potential for time-varying con founding by changes in 
dispensing practice or coding, changes in composition of 
the population being studied, or co-occurring interventions 
(table). We chose med ications for managing epilepsy as 
the control, because neither smoking status nor second-
hand smoke exposure are known to affect epilepsy onset 
or severity or the pharmacokinetics of these medications, 
and dispensing rates were likely to be high enough to 
provide sufficient statistical power. Gabapentin and 
pregabalin were excluded from the control group due to 
their reclassification as class C controlled substances 
under the Misuse of Drugs Act 1971 during the study 
period, in October, 2018, and their potential for misuse 
(which might have resulted in displacement use following 
the withdrawal of tobacco).
We considered and rejected the possibility of using 
medication dispensing among the non-prison population 
of Scotland as a control series, due to differences in 
population characteristics and co-occurring interventions 
that were likely to undermine the strength of the 
counterfactual, and pragmatic challenges in obtaining 
national community dispensing data.
Statistical analysis 
To distinguish the effects of policy announcement 
and implementation, we divided the analysis period 
(March 30, 2014, to Nov 30, 2019) into three phases: 
pre-announcement (March 30, 2014, to July 17, 2017); 
anticipatory (July 18, 2017, to Nov 29, 2018); and 
post-implementation (Nov 30, 2018, to Nov 30, 2019). The 
design and analysis were prespecified in a published 
protocol.12 Changes to the protocol are described in the 
appendix (p 4).
We analysed the data using auto-regressive integrated 
moving average (ARIMA) models, including seasonal 
ARIMA (SARIMA) models where appropriate, to 
account for underlying secular trends, seasonality, and 
auto correlation. We modelled the coefficients for step 
and slope changes in dispensing rates at the transition 
points between the pre-announcement, anticipatory, 
and post-implementation phases, using indicator 
variables reflecting the dates of policy announcement 
and implementation. Since overcrowding is ack-
nowledged as an important determinant of health in 
the prison setting, a crowding indicator for use as a 
covariate in sensitivity analyses was calculated on the 
basis of the ratio of the observed fortnightly mean 
population to the contracted capacity (ie, the number of 
people in custody that the prison is contracted by the 
Scottish Prison Service to hold) of the prison estate 
recorded for that period. The choice of model was based 
on the Box-Jenkins three-step approach of identification 
of auto-regressive and moving average components, 
using autocorrelation and partial autocorrelation 
functions; model estimation; and diagnostic checking, 
using the Portmanteau Q statistic for white noise 
residuals, kernel density plots to assess normality of 
residuals, and the Akaike Information Criterion and 
Bayesian Information Criterion for each model.13 We 
first modelled the whole time series before modelling 
Announcement (July 17, 2017) Implementation (Nov 30, 2018)
Step Slope Step Slope
Coefficient (95% CI) p value Coefficient (95% CI) p value Coefficient (95% CI) p value Coefficient (95% CI) p value
Treatment for nicotine dependence
All* –204·8 (–1564·7 to 1155·2) 0·768 12·6 (–28·1 to 53·4) 0·544 2249·6 (1874·9 to 2624·4) <0·0001 –2·6 (–44·4 to 39·1) 0·901
Nicotine replacement therapy* –256·8 (–1244·6 to 731·0) 0·610 16·0 (–13·2 to 45·1) 0·283 2108·6 (1701·3 to 2515·9) <0·0001 1·1 (–26·1 to 28·3) 0·936
Other (varenicline or bupropion)† –4·9 (–46·3 to 36·5) 0·817 0·1 (–2·1 to 2·3) 0·953 48·2 (20·0 to 76·5) 0·0008 –9·1 (–14·4 to –3·8) 0·001
Smoking-associated illness
All –76·4 (–458·9 to 306·1) 0·695 –23·9 (–41·4 to –6·4) 0·007 –646·2 (–1110·9 to –181·4) 0·006 16·5 (–13·6 to 46·7) 0·282
Respiratory 65·7 (–130·4 to 261·9) 0·511 –4·3 (–13·0 to 4·4) 0·330 –485·9 (–746·7 to –225·1) 0·0003 –11·0 (–24·7 to 2·7) 0·114
Cardiovascular –105·6 (–191·4 to –19·8) 0·016 1·3 (–1·9 to 4·5) 0·418 –49·6 (–170·8 to 71·6) 0·422 –2·2 (–9·4 to 5·1) 0·561
Gastrointestinal –73·9 (–303·7 to 156·0) 0·529 –21·0 (–32·3 to –9·7) <0·0001 –137·3 (–507·6 to 233·1) 0·468 30·2 (8·6 to 51·7) 0·006
Sensory 1·4 (0·1 to 2·6) 0·032 –0·1 (–0·2 to 0·0) 0·002 –0·8 (–3·5 – 1·8) 0·541 0·2 (0·0 to 0·3) 0·017
Mental health
All antidepressants† –119·7 (–270·2 to 30·7) 0·119 –2·9 (–11·5 to 5·6) 0·502 151·7 (–114·2 to 417·5) 0·263 0·5 (–12·6 to 13·6) 0·940
SSRI antidepressants† –121·3 (–171·9 to –70·7) <0·0001 –3·1 (–5·7 to –0·5) 0·020 18·2 (–52·0 to 88·4) 0·611 3·2 (–0·1 to 6·4) 0·054
Control series
Antiepileptic drugs† –19·0 (–94·8 to 56·8) 0·623 2·1 (–1·3 to 5·5) 0·230 –70·9 (–184·8 to 43·1) 0·223 –0·7 (–6·6 to 5·2) 0·820
SARIMA=seasonal auto-regressive integrated moving average. SSRI=selective serotonin reuptake inhibitor. *Analyses of nicotine replacement therapy and the nicotine replacement therapy component of the 
combined nicotine dependence category excluded one closed prison for which nicotine replacement therapy was dispensed via an in-reach service provided by the local health board, rather than the national 
pharmacy contract, and for which detailed data on nicotine replacement therapy dispensing were therefore not available; data for this prison were included in all other analyses. †SARIMA models provided the 
best model fit for these outcomes considering seasonality in dispensing associated with the Christmas period.
Table: SARIMA modelling of changes in fortnightly dispensing rates per 1000 people in custody at smoke-free policy announcement and policy implementation for closed prisons in Scotland
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and testing the effect of policy announcement and 
implementation (appendix p 6).
The impact of the smoke-free policy was hypothesised to 
differ in important ways in open versus closed estab-
lishments, because people in custody in Scotland’s open 
prison might smoke on periods of home leave, or while 
working outside of the prison. Primary analyses therefore 
comprised fortnightly dispensing rates for the 14 closed 
prisons in Scotland. For primary analyses, we additionally 
calculated relative effect estimates for step and slope 
changes by applying the absolute coefficients for the 
change obtained from ARIMA or SARIMA modelling to 
mean dispensing rates immediately preceding announce-
ment and implementation (appendix p 7).
We did prespecified secondary analyses comprising: all 
15 prisons in Scotland (open and closed); indicator 
saturation to identify step or slope changes not specified 
a priori;14 weekly time series; and adjustment for the 
crowding indicator. Since qualitative analyses of TIPs 
suggested some stockpiled tobacco might have been in 
circulation immediately after implementation of the 
smoke-free policy, we did a post-protocol analysis to 
test whether specifying a later implementation date 
(Dec 30, 2018) provided a better model fit. Full results 
of secondary and post-protocol analyses are in the 
appendix (pp 7–14).
Data cleaning and ARIMA or SARIMA modelling were 
done using Stata software (version 16); indicator 
saturation analyses were done using R software 
(version 3.6.3) using the gets package.
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results 
The mean daily prison population during the study period 
was 7517 (SD 235·4, range 6984–8143) for the closed 
estate (primary analyses) and 7730 (235·4, 7185–8335) for 
all prisons (secondary analyses). 44 660 unique individuals 
were estimated to have spent time incarcerated in the 
closed estate in Scotland during the study period (primary 
analyses); and 44 775 individuals for all prisons (secondary 
analyses). A total of 148 fortnights (86 pre-announcement, 
35 in the anticipatory period, and 27 post-implementation) 
and 31·3 million eligible dispensed items; 3 324 178 items 
for nicotine dependence, 16 850 875 items for smoking-
associated illnesses, 9 214 162 items for mental health, 
1 885 990 for the control condition) were included in the 
analyses. Total dispensed quantities and mean rates for 
each medication category during the overall study period 
and each phase are shown in the appendix (p 5).
Within the overall category of medications for nicotine 
dependence, a 44% increase in dispensing was observed 
(figure 2A, table; appendix p 11), primarily driven by 
nicotine replacement therapy, which accounts for the 
majority of dispensing in this category. For nicotine 
replacement therapy, a 42% increase in dispensing 
associated with policy imple mentation was observed 
(2109 items per 1000 people in custody per fortnight, 
95% CI 1701–2516; figure 2B, table; appendix p 11).
Figure 2: Time-series analysis of fortnightly dispensing rate for medications for nicotine dependence in 
Scottish prisons during the study period 



























































































































C Other medications for nicotine dependence (varenicline or bupropion)
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An initial step increase in dispensing rates of other 
medications for nicotine dependence was observed 
(48 items per 1000 people in custody per fortnight, 
95% CI 20 to 77) with a negative slope change (–9 items, 
95% CI –14 to –4) at the point of policy implementation 
(figure 2C, table). Sensitivity analysis demonstrated that 
a delayed implementation date (Dec 30, 2018) provided a 
better fit to the data on dispensing of other medications 
for nicotine dependence, indicating that an initial peak 
immediately after implementation was followed by a 
sustained step decrease in dispensing (–80 items 
per 1000 people in custody per fortnight, 95% CI 
Figure 3: Time-series analysis of fortnightly dispensing rate for medications for smoking-associated illnesses in Scottish prisons during the study period
(A) All medications for smoking-associated illnesses. (B) Medications for respiratory illnesses. (C) Medications for cardiovascular illnesses. (D) Medications for gastrointestinal illnesses. (E) Medications 
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–106 to –53; appendix p 7) and a negative slope trend 
(–5 items, 95% CI –2 to –8).
For medications for smoking-related illnesses, primary 
analysis of the combined category suggested a negative 
slope change at the point of policy announcement 
(–24 items, 95% CI –41 to –6; 0·3% relative decrease) 
followed by a step decrease on implementation 
(–646 items per 1000 people in custody per fortnight, 
95% CI –1111 to –181; 9% relative decrease; figure 3A, 
table; appendix p 11).
For respiratory disease, a substantial step decrease 
was observed at the point of policy implementation 
(–486 items per 1000 people in custody per fortnight, 
95% CI –747 to –225; 11% relative decrease), which largely 
accounted for the observed decrease in overall smoking-
related illness dispensing (figure 3B, table).
For cardiovascular conditions, a substantial step 
decrease was observed at the point of policy announce-
ment (figure 3C, table), although the 95% CIs were wide 
(–106 items per 1000 people in custody per fortnight, 
95% CI –191 to –20; 44% relative decrease). No other 
significant changes in dispensing for cardiovascular 
conditions were observed.
For gastrointestinal diseases, there was a pre-existing 
upward trend in dispensing rates, which plateaued at the 
point of policy announcement and subsequently resumed 
at the point of implementation (figure 3D, table). For the 
sensory disease category, dispensing rates were low 
overall (figure 3E). Modelling suggested a similar pattern 
to gastrointestinal diseases, with a small step increase 
observed at announcement, but the absolute changes 
were small (around 1 or fewer items per 1000 people in 
custody per fortnight; 0·1–0·2% relative change) and 
most confidence intervals included zero (table).
No significant changes in dispensing rates of anti-
depressant medications were observed in association 
with policy announcement or implementation in either 
primary (figure 4A, table) or sensitivity analyses (appendix 
p 7). For the subgroup of SSRI antidepressants, policy 
announce ment was associated with a negative step change 
(–121 items per 1000 people in custody per fortnight, 
95% CI –172 to –71; 12% relative decrease) and small 
negative slope change (–3 items, 95% CI –6 to 0; 
0·1% relative decrease), followed by a positive slope change 
of similar magnitude at the point of policy implementation 
(3 items, 95% CI 0 to 6; figure 4B, table).
No significant changes in the dispensing rates of 
antiepileptic medications (control) were observed at 
announcement or implementation (figure 5, table).
Indicator saturation results for nicotine replacement 
therapy, other medications for nicotine dependence, and 
respiratory medications confirmed substantial changes 
following policy implementation, with dates in 
December, 2018 (2–4 weeks after official imple mentation), 
identified as the key breakpoint for step changes 
(appendix p 12). For other outcomes, no significant 
changes associated with policy announce ment or 
implementation were identified. The modest step and 
slope changes in dispensing rates for non-respiratory 
smoking-associated illnesses observed in primary ana-
lyses were not confirmed by indicator saturation. Results 
of sensitivity analyses were otherwise consistent with the 
primary results, including those encompassing the open 
prison (appendix p 7). A post-hoc analysis of dispensing 
of hypnotic or anxiolytic medications did not identify 
any changes associated with policy announce ment or 
implementation (appendix p 7).
Discussion 
Implementation of a comprehensive smoke-free policy 
in Scottish prisons was associated with increased overall 
provision of treatment to support smoking cessation 
or abstinence, reflecting a substantial increase in the 
dispensing of nicotine replacement therapy and a smaller 
decline in dispensing of other medications (primarily 
varenicline) in this category. Implementation was also 
associated with a sustained reduction in dispensing of 
medications for respiratory illness. A modest reduction 
Figure 4: Time-series analysis of fortnightly dispensing rate for antidepressant medications in Scottish 
prisons during the study period 
































































































B Selective serotonin reuptake inhibitors
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in dispensing for acute angina at the point of 
announcement and temporary changes in dispensing 
for sensory and gastrointestinal symptoms were not 
corroborated in sensitivity analyses using an alternative 
modelling approach. We found no evidence of increased 
dispensing for depression and anxiety, and, when 
examining medications most specific to these indications, 
a suggestion of short-term reductions in dispensing.
To our knowledge, this is the first analysis to use 
medication dispensing to assess the impact of smoke-free 
policies in institutional settings on outcomes other than 
smoking cessation or abstinence attempts, and forms 
part of the first study internationally to assess imple-
mentation of a comprehensive smoke-free policy across 
an entire prison system.
Previous studies have reported changes in prescribing 
of nicotine replacement therapy following smoke-free 
policies in psychiatric hospitals, although these were 
simple comparisons done before and after policy 
implementation that did not account for secular trends, 
seasonality, or autocorrelation.15–17 Our observation of 
increased nicotine replacement therapy dispensing is 
consistent with these studies and findings from the 
qualitative data collected as part of TIPs, which described 
extensive preparations across the Scottish Prison Service 
for increased demand for cessation or abstinence 
support.11 The observed decline in dispensing of other 
medications used to support cessation or abstinence 
attempts might be explained by multiple factors, 
including a decline in opportunities to prescribe 
varenicline for the licensed indication of cessation of 
tobacco smoking; the increased availability of nicotine 
replacement therapy, which is recommended as first line 
in local formularies in Scotland and is substantially 
cheaper than other medications used to support cessation 
or abstinence attempts; and widespread availability and 
uptake of rechargeable e-cigarette devices.18
Our finding of decreased dispensing for respiratory 
conditions following policy implementation is consistent 
with studies of the association between ambient air 
quality and medication dispensing, which found a 
consistent positive association between dispensing for 
chronic respiratory conditions and airborne pollutant 
levels,19–21 and with observed reductions in respiratory 
symptoms and hospital admissions after community 
smoke-free legislation.22 By documenting the impact of 
a clearly defined intervention in a closed setting with 
substantial improvement in measured air quality,10 our 
study addresses some limitations of existing community-
based outcome studies, for which exposure measurement 
is more challenging.21
Fewer studies have investigated the association 
between air quality (indoor or outdoor) and dispensing 
for non-respiratory outcomes than for respiratory 
outcomes.23 We found a potential modest impact of policy 
announcement on dispensing for acute angina, and no 
clear effect in either direction for dispensing for gastro-
oesophageal reflux disease and conjunctivitis, none of 
which were replicated in secondary analyses using 
indicator saturation (ie, where dates of interest are 
identified by testing for potential breaks at every point in 
the time series rather than prespecified). These findings 
might reflect low rates of dispensing (for cardiovascular 
and sensory illnesses) or weaker associations with first-
hand or second-hand smoke exposure (for gastrointestinal 
and sensory illnesses) for these outcomes. The 
inconclusive results for cardiovascular dispensing 
contrast with the strong evidence of a reduction in 
cardiovascular events following smoking bans in 
community settings24 and might reflect the relatively 
young population in Scottish prisons (mean age 36 years 
in 2019–20),25 although this population are at risk of 
accelerated onset of long-term conditions and 
multimorbidity.26 Long-term studies of cardiovascular 
impacts of smoke-free policies, especially among older 
people in custody and those serving longer sentences, 
are warranted.
Our findings on smoking-associated illness among 
people in custody are corroborated by a parallel arm 
of TIPs, which reported reductions in recorded staff 
sickness absence overall and for cardiothoracic 
conditions after policy implementation.11 The absence of 
changes in antidepressant or hypnotic or anxiolytic drug 
dispensing among people in custody is reassuring, 
especially considering the broader evidence base that 
smoking cessation can have mental health benefits,27 but 
should be interpreted with caution since medication 
dispensing is a crude indicator of potential mental 
health impacts and might not capture hetero geneous 
effects—eg, among people in custody at high risk of poor 
mental health. In TIPs surveys, two-thirds of people in 
custody reported that the smoking ban had made them 
more anxious and only 12% agreed it had made them 
happier, although response rates were low.11
Figure 5: Time-series analysis of fortnightly dispensing rate for antiepileptic medications in Scottish prisons 
during the study period
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A major strength of this study is its national coverage, 
with comprehensive outcome data covering almost all 
dispensing episodes in Scottish prisons during the study 
period (with the exception of nicotine replacement 
therapy for one prison, which was omitted from analyses 
for that outcome). Our time-series analysis used data 
collected over a longer duration than most similar 
studies,8,28 which increases the likelihood of detecting 
subtle effects and adequately accounting for seasonal and 
secular trends. Our use of pharmacy contract data 
collected for the purposes of financial reimbursement is 
likely to maximise validity in terms of data quality and 
completeness. Use of a consistent single source of 
administrative data for outcome measurement through-
out the time series also helps mitigate against artifactual 
changes over time (instrumentation bias). The absence 
of effect in a control series of medications increases our 
confidence in inferring a causal relationship between the 
smoke-free policy and observed changes in dispensing.28 
We were not able to include a control series of prisons 
where the intervention was not implemented, since the 
policy was introduced in all Scottish prisons simul-
taneously, or to investigate heterogeneity of impacts 
within the prison population. We also were unable to 
include data on rechargeable e-cigarette use, which 
might have affected dispensing to support smoking 
cessation or abstinence following their introduction 
2 months before implementation of the smoke-free 
policy.11
Medication dispensing has not, to our knowledge, 
previously been used to investigate smoke-free policies 
in custodial settings, although it has been extensively 
used as an outcome in studies of the health impacts 
of outdoor air quality21 and as part of a composite 
outcome for monitoring respiratory symptoms following 
implementation of community smoke-free policies in 
one study.29 The use of medication dispensing as a proxy 
indicator of health impacts has advantages and 
limitations. Medication dispensing is an objective 
indicator of health impacts that avoids response bias and 
captures relatively mild conditions or those usually 
managed in primary care, which might have substantial 
human and economic costs. Most other studies of public 
or institutional smoke-free policies have focused on 
hospital admissions or mortality, which represent only 
one component of the broader health impact of smoke-
free policies. Although dispensing might not always 
reflect use, it does reflect demand and thus is a reasonable 
proxy for symptoms: this might be especially true in 
closed settings such as prisons. However, some of 
our medication categories, such as antibiotics and 
antidepressants, were non-specific for the outcomes of 
interest because data on reason for dispensing were not 
available: this might have resulted in bias towards the 
null for relative effect estimates, although this should not 
have affected estimates of absolute changes. In particular, 
antidepressant dis pensing is a crude indicator of 
consequences for mental health, and data from the 
survey and qualitative components of the TIPs suggest 
that these impacts should not be overlooked.11
Our results suggest that smoke-free prison policies 
have beneficial effects on acute respiratory illness 
during imprisonment. However, since most people in 
prison globally are in pre-trial detention or serving short 
sentences, with the average time served by people in 
prison custody in Scotland less than 6 months,25 the 
long-term impact of such policies will depend on 
whether these policies encourage sustained abstinence 
from smoking outside the prison environment. 
Evidence to date suggests that smoking relapse rates are 
high after release from smoke-free prisons, although 
such policies might reduce the intensity of smoking 
after release.30 Prison smoke-free policies must therefore 
form part of a comprehensive package of tobacco control 
measures encompassing both com munity and custodial 
settings, and broader efforts to address health 
inequalities among people who experience incarc-
eration.31 In addition to work to quantify and support 
sustained behavioural change, future studies of smoke-
free prison policies should investigate longer-term 
health impacts among people in custody and staff, 
perhaps using linkage between prison records and 
primary or secondary health-care data on diagnoses and 
hospital admissions.
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